A UBS analyst increased the price target for Kodiak Sciences from $120 to $150.

Nov 13, 2026, 6:08 PM ETOpinionRead the original at moomoo.com

Good for KOD

UBS reaffirmed its positive view and raised its target from $120 to $150, an encouraging signal for Kodiak. The report gives no new company results or drug news.

KOD · Kodiak Sciences Inc.

AI read · Good for KOD

The AI's read

That higher target shows UBS sees more value in Kodiak than before. It is an analyst's opinion, not a change in Kodiak's sales, cash, or drug progress, so the positive signal is limited.

Get alerts for KOD

Follow Kodiak Sciences Inc. (KOD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KOD

Free on the App Store and Google Play, or on the web.